（文章来源：每日经济新闻） 福安药业（300194.SZ）10月10日在投资者互动平台表示，公司子公司持有喷他佐辛注射液、咪达唑仑 注射液等麻醉药品注册证书，目前咪达唑仑注射液有在生产销售，但销量很小，对当前公司总体经营业 绩没有重大影响。 每经AI快讯，有投资者在投资者互动平台提问：公司在麻醉药品领域目前药品储备和销售情况怎么 样？在国内麻醉药市场处于什么地位？ ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating challenges in the market despite some growth in specific segments [1] Financial Performance - The company's operating revenue was approximately 4.639 billion yuan, a year-on-year decrease of 1.98% [1] - Net profit attributable to shareholders was about 224 million yuan, down 15.69% year-on-year [1] - Basic earnings per share stood at 0.32 yuan [1] Product Development and Market Position - The company launched 10 new formulation products in the first half of the year [1] - A total of 19 products across 25 specifications were awarded national procurement bids [1] - The formulation processing and export business maintained stable growth, with significant development in self-operated formulation exports [1] Production and Innovation - The company focused on cost reduction and leveraged its production advantages in key raw materials, resulting in increased production of 11 key raw materials such as ibuprofen and aspirin, thereby expanding market share [1] - Sales of specialty raw materials experienced rapid growth [1] - In the first half of the year, the company obtained 21 drug approvals, including 19 new formulation products and 2 raw material drug approvals [1] - The company initiated Phase II clinical work for a Class I innovative drug OAB-14 for Alzheimer's treatment [1] - The company received 18 authorized patents, including 8 invention patents [1] - One project was awarded the Shandong Province 2024 Science and Technology Progress Award, and another was included in the 2025 provincial major science and technology innovation project [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating challenges in the market despite some growth in specific areas [1] Financial Performance - The company's operating revenue was approximately 4.639 billion yuan, a year-on-year decrease of 1.98% [1] - Net profit attributable to shareholders was about 224 million yuan, down 15.69% year-on-year [1] - Basic earnings per share stood at 0.32 yuan [1] Product Development and Market Position - The company launched 10 new formulation products in the first half of the year [1] - A total of 19 products with 25 specifications were awarded national procurement bids by the end of the reporting period [1] - The formulation processing and export business maintained stable growth, with significant development in self-operated formulation exports [1] Raw Material Production and Innovation - The company leveraged its production advantages in key raw materials, achieving increased production of 11 key raw materials including ibuprofen and aspirin, thereby expanding market share [1] - Sales of specialty raw materials experienced rapid growth [1] - The company obtained 21 drug approvals in the first half of the year, including 19 new formulation products and 2 raw material drug approvals [1] - It initiated Phase II clinical trials for a Class 1 innovative drug OAB-14 for Alzheimer's treatment [1] - The company received 18 authorized patents, including 8 invention patents [1] Recognition and Future Projects - One project was awarded the Shandong Province 2024 Science and Technology Progress Second Prize [1] - Another project was included in the 2025 provincial major scientific and technological innovation engineering projects [1]